Telesis Bio Inc

Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. It offers BioXp 3200 system and Gibson assembly reagents. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.

Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates

-- Total revenue of $6.3M in 1QFY23 -- BioXp® franchise revenue increased by 28% SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the first quarter of 2023. “We are pleased with our company's performance this quarter where we delivered 28% growth year over year in BioXp franchise revenue while improving gross margins and holding operating expenses steady,” said Todd R.

Telesis Bio Reports First Quarter 2023 Financial Results

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, May 11, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.

Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023

New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic Biology Workstation New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic Biology Workstation

Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up

Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conference Call Participants Brandon Couillard - Jefferies Harrison Schrage - KeyBanc Capital Markets Poon Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to the Q4 2022 Telesis Bio Earnings Conference Call. [Operator Instructions].

Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript

Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates

-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21

Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance

Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions”

Telesis Bio to Present at Festival of Biologics Conference

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Should You Buy Telesis Bio (TBIO) After Golden Cross?

Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA

Telesis Bio to Present at RNA Leaders Europe Congress

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, March 21, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.

Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the company's chief executive officer, will participate in a fireside chat with Steven Mah at the 43rd Annual Cowen Healthcare Conference on Monday, March 6th at 12:50 PM Eastern Time/ 9:50AM Pacific Time. Additionally, Todd will participate in a ‘Synthetic Biology Enabling Technologies Panel' on Tuesday, March 7th at 4:40pm Eastern time / 1:40 pm Pacific Time.

Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference

Scientists Can Now Begin the mRNA Synthesis Process from Their Own Sequence or Plasmid DNA Scientists Can Now Begin the mRNA Synthesis Process from Their Own Sequence or Plasmid DNA

Telesis Bio Releases BioXp® Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation

Sanofi

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company's common stock to twenty new employees. These grants were made pursuant to the Company's 2021 Inducement Stock Incentive Plan, were approved by the Company's compensation committee of the board of directors, and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Lydall

New Senior Investment Group

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY  10036 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Perpetual Federal Savings Bank (OTC: PFOH) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Perpetual Federal Savings Bank (OTC: PFOH) in connection with the proposed acquisition of the company by Farmers & Merchants Bancorp, Inc. ("FMAO").

SHAREHOLDER ALERT: WeissLaw LLP Reminds PFOH, TBIO, LDL, and SNR Shareholders About Its Ongoing Investigations

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Translate Bio, Inc. ("TBIO" or the "Company") ( TBIO ) relating to its proposed acquisition by Sanofi. Under the terms of the agreement, TBIO shareholders will receive $38.00 in cash per share.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Translate Bio, Inc. - TBIO

Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest in selling off around 25% of its shares in the company, which it had been working with since 2018. Translate Bio filed SEC document to give an inside look at how the buyout negotiations played out.

Inside Sanofi's $3.2B Translate Bio Buyout

-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary  conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA technology across vaccines and therapeutics development -- -- Advanced mRNA infectious disease vaccine programs, including Sanofi Pasteur initiation of influenza clinical trial; clinical trial results from two mRNA vaccines anticipated this year --

Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Translate Bio (NasdaqGS: TBIO) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Translate will receive only $38.00 in cash for each share of Translate that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe

TRANSLATE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Translate Bio - TBIO

The biotech is being bought for $3.2 billion.

Why Translate Bio Stock Soared Today

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Translate Bio, Inc. ("Translate" or the "Company") (NASDAQ: TBIO) in connection with the proposed acquisition of the Company by Sanofi ("Sanofi") (NASDAQ: SNY) via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $38.00 in cash for each share of Translate common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Translate Bio, Inc.

MILWAUKEE, Aug. 3, 2021 /PRNewswire/ -- Ademi LLP is investigating Translate Bio (NASDAQ: TBIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to learn how to join the action: https://www.ademilaw.com/case/translate-bio-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Translate Bio, Inc. has obtained a Fair Price in its transaction with Sanofi

Biotech stocks surge after big news & bullish analyst ratings. The post Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Translate Bio, Inc. (NASDAQ: TBIO) to Sanofi for $38.00 per share in cash is fair to Translate Bio shareholders. Halper Sadeh encourages Translate Bio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Trans

Translate Bio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Translate Bio, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – TBIO

News for Telesis Bio Inc Stock (TBIO)